Inmedix UK Ltd 10605553 false 2025-01-01 2025-12-31 2025-12-31 The principal activity of the company is Life sciences diagnostic and therapeutic Digita Accounts Production Advanced 6.30.9574.0 true 10605553 2025-01-01 2025-12-31 10605553 2025-12-31 10605553 bus:OrdinaryShareClass1 2025-12-31 10605553 core:CurrentFinancialInstruments 2025-12-31 10605553 core:CurrentFinancialInstruments core:WithinOneYear 2025-12-31 10605553 bus:SmallEntities 2025-01-01 2025-12-31 10605553 bus:AuditExemptWithAccountantsReport 2025-01-01 2025-12-31 10605553 bus:FilletedAccounts 2025-01-01 2025-12-31 10605553 bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 10605553 bus:RegisteredOffice 2025-01-01 2025-12-31 10605553 bus:Director1 2025-01-01 2025-12-31 10605553 bus:Director2 2025-01-01 2025-12-31 10605553 bus:OrdinaryShareClass1 2025-01-01 2025-12-31 10605553 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 10605553 bus:Agent1 2025-01-01 2025-12-31 10605553 countries:EnglandWales 2025-01-01 2025-12-31 10605553 2024-01-01 2024-12-31 10605553 2024-12-31 10605553 bus:OrdinaryShareClass1 2024-12-31 10605553 core:CurrentFinancialInstruments 2024-12-31 10605553 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 10605553

Inmedix UK Ltd

Unaudited Filleted Financial Statements

for the Year Ended 31 December 2025

 

Inmedix UK Ltd

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 5

 

Inmedix UK Ltd

Company Information

Directors

Mr Daniel Keith Austen

Mr Andrew James Holman

Registered office

10 Prospect Place
Welwyn
Hertfordshire
AL6 9EW

Accountants

RS Partnership Ltd
Chartered Certified Accountants10 Prospect Place
Welwyn
Hertfordshire
AL6 9EW

 

Inmedix UK Ltd

(Registration number: 10605553)
Balance Sheet as at 31 December 2025

Note

2025
£

2024
£

Current assets

 

Debtors

4

172

93

Cash at bank and in hand

 

3,135

10,069

 

3,307

10,162

Creditors: Amounts falling due within one year

5

(273,864)

(244,063)

Net liabilities

 

(270,557)

(233,901)

Capital and reserves

 

Called up share capital

6

100

100

Retained earnings

(270,657)

(234,001)

Shareholders' deficit

 

(270,557)

(233,901)

For the financial year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 16 April 2026 and signed on its behalf by:
 

.........................................
Mr Andrew James Holman
Director

 

Inmedix UK Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
10 Prospect Place
Welwyn
Hertfordshire
AL6 9EW

The principal place of business is:
18 Pond Court
The Ridgeway
Codicote
Hertfordshire
SG4 8YY

These financial statements were authorised for issue by the Board on 16 April 2026.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

These financial statements are presented in Pounds Sterling (£), which is the Company’s functional
currency. All amounts have been rounded to the nearest pound, unless otherwise indicated.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

 

Inmedix UK Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 1 (2024 - 1).

4

Debtors

2025
£

2024
£

Prepayments

172

93

172

93

 

Inmedix UK Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

5

Creditors

Creditors: amounts falling due within one year

Note

2025
£

2024
£

Due within one year

 

Amounts owed to group undertakings and undertakings in which the company has a participating interest

271,285

241,722

Accruals and deferred income

 

1,086

1,056

Directors Loan Account

 

1,493

1,285

 

273,864

244,063

6

Share capital

Allotted, called up and fully paid shares

2025

2024

No.

£

No.

£

Ordinary A of £1 each

100

100

100

100